NO991560L - PDE IV-inhiberende 2-cyanoiminoimidazol-derivater - Google Patents

PDE IV-inhiberende 2-cyanoiminoimidazol-derivater

Info

Publication number
NO991560L
NO991560L NO991560A NO991560A NO991560L NO 991560 L NO991560 L NO 991560L NO 991560 A NO991560 A NO 991560A NO 991560 A NO991560 A NO 991560A NO 991560 L NO991560 L NO 991560L
Authority
NO
Norway
Prior art keywords
pde
inhibiting
cyanoiminoimidazole
derivatives
cyanoiminoimidazole derivatives
Prior art date
Application number
NO991560A
Other languages
English (en)
Other versions
NO991560D0 (no
NO312960B1 (no
Inventor
Eddy Jean Edgard Freyne
Francisco Javi Fernsndez-Gadea
Josu Ignacio Andrus-Gil
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO991560D0 publication Critical patent/NO991560D0/no
Publication of NO991560L publication Critical patent/NO991560L/no
Publication of NO312960B1 publication Critical patent/NO312960B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/48Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO19991560A 1996-10-02 1999-03-30 PDE IV-inhiberende 2-cyanoiminoimidazol-derivater NO312960B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (en) 1996-10-02 1997-09-24 Pde iv inhibiting 2-cyanoiminoimidazole derivatives

Publications (3)

Publication Number Publication Date
NO991560D0 NO991560D0 (no) 1999-03-30
NO991560L true NO991560L (no) 1999-06-02
NO312960B1 NO312960B1 (no) 2002-07-22

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991560A NO312960B1 (no) 1996-10-02 1999-03-30 PDE IV-inhiberende 2-cyanoiminoimidazol-derivater

Country Status (31)

Country Link
US (1) US6051718A (no)
EP (1) EP0934280B1 (no)
JP (1) JP3068208B2 (no)
KR (1) KR100520002B1 (no)
CN (1) CN1106387C (no)
AR (1) AR008875A1 (no)
AT (1) ATE236884T1 (no)
AU (1) AU719561B2 (no)
BG (1) BG64278B1 (no)
BR (1) BR9712256B1 (no)
CA (1) CA2267322C (no)
CY (1) CY2380B1 (no)
CZ (1) CZ297474B6 (no)
DE (1) DE69720757T2 (no)
DK (1) DK0934280T3 (no)
EE (1) EE03825B1 (no)
ES (1) ES2196308T3 (no)
HK (1) HK1020344A1 (no)
HU (1) HU225158B1 (no)
IL (2) IL129298A0 (no)
MY (1) MY116980A (no)
NO (1) NO312960B1 (no)
NZ (1) NZ334971A (no)
PL (1) PL194673B1 (no)
PT (1) PT934280E (no)
RU (1) RU2180902C2 (no)
SI (1) SI0934280T1 (no)
SK (1) SK285878B6 (no)
TR (1) TR199900732T2 (no)
UA (1) UA62939C2 (no)
WO (1) WO1998014432A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298747B6 (cs) 1998-04-01 2008-01-16 Janssen Pharmaceutica N. V. Derivát pyridinu, způsob jeho výroby a použití a farmaceutická kompozice s jeho obsahem
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2002085855A1 (fr) * 2001-04-19 2002-10-31 Eisai Co., Ltd. Derives de 2-iminopyrrolidine
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
US20040220227A1 (en) * 2001-07-11 2004-11-04 Shinji Ina Remedies for allergic eye diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
BRPI0117198B1 (pt) 2001-12-14 2018-03-13 Merck Serono S.A. Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
EP2444393A1 (en) 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9957247B2 (en) * 2012-06-07 2018-05-01 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
NZ254881A (en) * 1992-07-28 1996-09-25 Rhone Poulenc Rorer Ltd Diether, dithioether or diether thioether derivatives of 1,2-dihydroxybenzenes substituted in position-4 by an (hetero)aryl-containing group;
PL309257A1 (en) * 1992-12-02 1995-10-02 Pfizer Pirocatechin doethers as selective inhibitors of ped iv
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Pde▲iv▼およびtnf抑制剤としての化合物
JPH09502170A (ja) * 1993-08-19 1997-03-04 スミスクライン・ビーチャム・コーポレイション フェネチルアミン化合物
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
MX9700068A (es) * 1994-06-24 1997-12-31 Euro Celtique Sa Compuestos y metodo para inhibir a la fosfodiesterasa iv.
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
BG103220A (en) 1999-11-30
IL129298A (en) 2006-04-10
RU2180902C2 (ru) 2002-03-27
EP0934280A1 (en) 1999-08-11
NO991560D0 (no) 1999-03-30
BR9712256A (pt) 1999-08-24
ATE236884T1 (de) 2003-04-15
PT934280E (pt) 2003-08-29
BR9712256B1 (pt) 2011-04-19
BG64278B1 (bg) 2004-08-31
DE69720757D1 (de) 2003-05-15
ES2196308T3 (es) 2003-12-16
CN1232456A (zh) 1999-10-20
EE03825B1 (et) 2002-08-15
IL129298A0 (en) 2000-02-17
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
KR100520002B1 (ko) 2005-10-13
MY116980A (en) 2004-04-30
SK34499A3 (en) 2000-04-10
AR008875A1 (es) 2000-02-23
CA2267322C (en) 2007-11-06
SI0934280T1 (en) 2003-12-31
HUP9904063A2 (hu) 2000-09-28
DE69720757T2 (de) 2004-03-04
NZ334971A (en) 2000-09-29
DK0934280T3 (da) 2003-07-21
JP3068208B2 (ja) 2000-07-24
PL194673B1 (pl) 2007-06-29
WO1998014432A1 (en) 1998-04-09
HK1020344A1 (en) 2000-04-14
CZ102899A3 (cs) 1999-07-14
AU4779297A (en) 1998-04-24
US6051718A (en) 2000-04-18
NO312960B1 (no) 2002-07-22
CY2380B1 (en) 2004-06-04
EE9900112A (et) 1999-10-15
PL332573A1 (en) 1999-09-27
CZ297474B6 (cs) 2006-12-13
AU719561B2 (en) 2000-05-11
HU225158B1 (en) 2006-07-28
CN1106387C (zh) 2003-04-23
CA2267322A1 (en) 1998-04-09
EP0934280B1 (en) 2003-04-09
HUP9904063A3 (en) 2000-11-28
SK285878B6 (sk) 2007-10-04
UA62939C2 (uk) 2004-01-15
JP2000503678A (ja) 2000-03-28

Similar Documents

Publication Publication Date Title
ATE215950T1 (de) Carbolinderivate
DK0901474T3 (da) Arylpyrimidinderivater
ATE261942T1 (de) 6-phenylpyridinderivate
DK0934320T3 (da) Naphthyridinderivater
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
DE69817186D1 (de) Diaminorhodamin-derivate
NO981946D0 (no) Imidazoquinazolin-derivater
NO991560L (no) PDE IV-inhiberende 2-cyanoiminoimidazol-derivater
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
ATE255098T1 (de) Substituierte chromanderivate
ATE255099T1 (de) Substituierte chromanderivate
DE69841086D1 (de) 5-Deoxy-Cytidin-Derivate
ZA978809B (en) PDE IV inhibiting 2-cyanoiminoimidazole derivatives
IS5026A (is) 2-metoxýfenýlpíperasín afleiður
DK1068194T3 (da) PDE IV-hæmmende pyridinderivater
ATE292632T1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin- derivate
DE69828780D1 (de) Amidinocamptpthecin-derivate
NO981495D0 (no) Phenoxymetylpiperidin-derivater
DK0966437T3 (da) 5-Aroylnaphthalenderivater
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
DE69710921D1 (de) Heterocyclische substituierte pyrrolidinamid-derivate
ATA69896A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate
ATA73396A (de) 3-methylimino-3-cephemderivate 3-methylimino-3-cephemderivate

Legal Events

Date Code Title Description
MK1K Patent expired